Puma Biotechnology Secures $125M Note Purchase By Athyrium Capital
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that it has entered into a note purchase agreement with a fund of Athyrium Capital Management, LP, a specialized asset management company